Home / Insights / Next early phase destinations

insights-espresso-icon whitepaper

Next early phase destinations

Espresso-live Speakers
by Mathini Ilancheran , Senior Research Analyst
12 December 2014

There has been a continuous increase in the conduct of Phase I trials in emerging destinations of Australia, China, Russia, Singapore and South Korea. Though developed markets of North America and Europe hold greater than 70% of the complex Phase I trials, majority of the Phase I bioequivalence and certain special population FIH studies are carried out in emerging countries of the Asia Pacific region. Now that the emerging countries are identified, the next phase would be to decide on the market to enter. During this phase, there is a prerequisite to understand the key parameters that needs to be taken into consideration while making a sourcing decision involving low cost country outsourcing. This paper will evaluate the crucial parameters for each country within the phase I emerging markets and arrive at the next best destinations for early phase clinical trial outsourcing.

Linkedin Twitter Facebook
Leave a comment

Please enter a valid name

Post your comment

Please select captcha


Get more stories like this

Subscirbe for more news,updates and insights from Beroe

Get Ahead with AI-Enabled Market Insights Schedule a Demo Now

Schedule a Demo Now